ON February 22, 2022 Huahui Health reported successful completion of first patient dosing of Phase I trial of HH-101, an Fc-enhanced anti-TIGIT antibody (Press release, Huahui Health, FEB 22, 2022, View Source [SID1234642184]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HH-101 has demonstrated superior anti-tumor effects and a good safety profile in pre-clinical studies. The Phase I study aims to evaluate the safety, tolerability, PK and efficacy of HH-101 in patients with late-stage solid tumors.

The Leading PI, Prof. SHEN Lin at Beijing Cancer Hospital, commented on the Phase I study, "Compared with many other anti-TIGIT antibodies, HH-101 is with enhanced Fc region, which may potentially lead to more effective Treg depletion and consequently improved anti-tumor effects. Hopefully the superior pre-clinical efficacy data can be translated into improved patient outcomes through human studies. We wish to have a successful clinical development of HH-101, providing Chinese cancer patients with more therapeutic options."

"HH-101 is the first oncology pipeline asset of Huahui Health that has received IND approval and entered clinical development stage. This is a milestone for the company’s rapid growth, and a recognition of Huahui’s R&D capabilities in oncology," says Dr. Bin Chen, the CEO of Huahui Health. "We strive to innovate breakthrough therapies to transform patient lives across the globe, through our continued commitment and efforts in understanding the disease biology and translating science into medicine and improved clinical benefits."